2型糖尿病の治療のためのGIPR/GLP-1R/GCGRトライアゴニストとしての新種のペプチド
1Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
ACS medicinal chemistry letters
|August 20, 2025
まとめ
この特許出願は,GIPR,GLP-1R,GCGRを標的とした新しいペプチドトライアゴニストを導入します. この化合物は2型糖尿病,肥満,脂肪肝の治療に 有望な効果を示しています
科学分野:
- 薬剤化学
- 薬理学について
- 内分泌学
背景:
- 肥満と2型糖尿病 (T2DM) は,世界的な健康問題です.
- 現在のT2DMと肥満の治療には限界があり,新しい治療戦略が必要である.
- 胃抑制ポリペプチド受容体 (GIPR) とグルカゴン類ペプチド-1受容体 (GLP-1R) を標的とする受容体アゴニストは,治療上の利点を示した.
研究 の 目的:
- GIPR,GLP-1R,GCGRにおける活性を持つペプチドトライアゴニストの新種を明らかにする.
- 代謝疾患の管理のための独特の薬理学的プロファイルを持つ化合物を提示する.
- T2DM,肥満,非アルコール性脂肪肝に対する新しい治療法の開発のための基礎を提供すること.
主な方法:
- ペプチドトリアゴニストの合成と特徴付け
- 受容体の活性に関する in vitro および in vivo 薬理学的評価
- 化合物の性質を最適化するための構造-活動関係の研究.
主要な成果:
- GIPR,GLP-1R,GCGRで強力で選択的な二重または三重アゴニズムを示すペプチドトライアゴニストの特定.
- 臨床前モデルでの好ましい薬動学的特性と in vivo 効能の実証
- 代謝薬の発見のための新しい化学的支架の確立
結論:
- 新種のペプチドトリアゴニストは 新しい治療法として有望です
- これらの化合物は,2型糖尿病,肥満,非アルコール性脂肪肝疾患の治療の可能性を提供します.
- これらのトリアゴニストのさらなる開発は,代謝障害の患者の改善につながる可能性があります.
関連する概念動画
Glucagon-like Receptor Agonists
415
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
415
Dipeptidyl Peptidase 4 Inhibitors
249
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
249
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K


